Log in  First Connection?

LungArchives

A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer
Lung
 5 min.

 Published on 18/02/2025 |  Original article (Full-text)  | Wu Dongsheng et al. | BMC Cancer 2025; 25(1): 236

Lung cancer remains the leading cause of cancer-related death worldwide [1], with non-small cell lung cancer (NSCLC) representing about 85% of all diagnosed lung cancer cases [2]. Recent advancements in computed tomography (CT) screening, coupled with growing public health awareness, have contributed...

Role of NAT10-mediated ac4C acetylation of ENO1 mRNA in glycolysis and apoptosis in non-small cell lung cancer cells
Lung
 5 min.

 Published on 18/02/2025 |  Original article (Full-text)  | Yuan Yanqing et al. | BMC Pulmonary Medicine 2024; 25(1): 75

Lung cancer is the most common cause of cancer-related deaths worldwide. More than 85% of lung cancer cases are classified as non-small cell lung cancer (NSCLC), with a predicted 5-year survival rate of only about 15.9% [1]. Over the past two decades, multidisciplinary efforts and technological advances...

PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer
Lung
 4 min.

 Published on 18/02/2025 |  Original article (Full-text)  | Wang Haitao et al. | BMC Cancer 2025; 25(1): 263

Epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) therapy has significantly improved clinical outcomes for patients with non-small cell lung cancer (NSCLC), being a standard treatment modality in various guidelines. While notable efficacy has been demonstrated in these NSCLC...

Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapy
Lung
 10 min.

 Published on 13/02/2025 |  Original article (Full-text)  | Yao Yuanshan et al. | Cancer Immunology, Immunotherapy 2025; 74(3): 101

Non-small cell lung cancer (NSCLC) represents the most prevalent subtype of lung cancer, accounting for approximately 85% of all lung cancer cases [1]. It encompasses several histological subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [2]. The etiology of NSCLC...

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Lung
 5 min.

 Published on 13/02/2025 |  Original article (Full-text)  | Zhang Jing et al. | BMC Pulmonary Medicine 2025; 25(1): 63

Mutations in the epidermal growth factor receptor (EGFR) represent a prevalent target in non-small cell lung cancer (NSCLC), with EGFR exon 20 insertion (ex20ins) mutations occurring in approximately 2–3% of cases [1]. These mutations, constituting the third most common EGFR mutation subtype following...